Lantern Pharma Statistics
Total Valuation
Lantern Pharma has a market cap or net worth of $53.27 million. The enterprise value is $45.66 million.
| Market Cap | 53.27M |
| Enterprise Value | 45.66M |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lantern Pharma has 12.76 million shares outstanding. The number of shares has increased by 2.25% in one year.
| Current Share Class | 12.76M |
| Shares Outstanding | 12.76M |
| Shares Change (YoY) | +2.25% |
| Shares Change (QoQ) | -0.57% |
| Owned by Insiders (%) | 3.63% |
| Owned by Institutions (%) | 14.15% |
| Float | 10.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 13.29 |
| P/TBV Ratio | 15.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.87, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.87 |
| Quick Ratio | 1.68 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -157.37% and return on invested capital (ROIC) is -101.40%.
| Return on Equity (ROE) | -157.37% |
| Return on Assets (ROA) | -73.31% |
| Return on Invested Capital (ROIC) | -101.40% |
| Return on Capital Employed (ROCE) | -482.04% |
| Weighted Average Cost of Capital (WACC) | 17.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$994,489 |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.43% in the last 52 weeks. The beta is 2.33, so Lantern Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.33 |
| 52-Week Price Change | +27.43% |
| 50-Day Moving Average | 3.15 |
| 200-Day Moving Average | 3.22 |
| Relative Strength Index (RSI) | 61.32 |
| Average Volume (20 Days) | 207,468 |
Short Selling Information
The latest short interest is 1.37 million, so 10.72% of the outstanding shares have been sold short.
| Short Interest | 1.37M |
| Short Previous Month | 1.48M |
| Short % of Shares Out | 10.72% |
| Short % of Float | 12.64% |
| Short Ratio (days to cover) | 5.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.61M |
| Pretax Income | -15.91M |
| Net Income | -15.91M |
| EBITDA | -16.59M |
| EBIT | -16.61M |
| Earnings Per Share (EPS) | -$1.44 |
Balance Sheet
The company has $6.32 million in cash and $59,076 in debt, with a net cash position of $6.26 million or $0.49 per share.
| Cash & Cash Equivalents | 6.32M |
| Total Debt | 59,076 |
| Net Cash | 6.26M |
| Net Cash Per Share | $0.49 |
| Equity (Book Value) | 3.45M |
| Book Value Per Share | 0.31 |
| Working Capital | 3.28M |
Cash Flow
In the last 12 months, operating cash flow was -$15.07 million and capital expenditures -$556, giving a free cash flow of -$15.07 million.
| Operating Cash Flow | -15.07M |
| Capital Expenditures | -556 |
| Depreciation & Amortization | 16,559 |
| Net Borrowing | n/a |
| Free Cash Flow | -15.07M |
| FCF Per Share | -$1.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lantern Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.25% |
| Shareholder Yield | -2.25% |
| Earnings Yield | -30.64% |
| FCF Yield | -29.03% |
Analyst Forecast
The average price target for Lantern Pharma is $20.00, which is 379.04% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.00 |
| Price Target Difference | 379.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |